ClinicalTrials.gg
CompletedNCT02993276Updated Sep 10, 2020

Evaluation of NEUROCAP® In the Treatment of Symptomatic Neuroma

An observational study in Neuroma, sponsored by Polyganics BV. Completed at 16 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-09-10.

Sponsored by Polyganics BV · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
73
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 25 studies in Neuroma with a site in United States — 4 open to participants now, 6 under way, none of them phase 3. Neuroma · United States.

Started
2017
with 3 others
Observational
7 of 25
1 open now
Registered
11th of 25
by date

Among the 25 studies in Neuroma with a site in United States, this one is one of 4 that started in 2017, is one of 7 observational ones, and was the 11th registered.

Neuroma

55 studies on the registry are indexed under Neuroma; 10 are open to participants now.

Browse Neuroma studies →

Open to participants now

4 of the 25 studies in Neuroma with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 7 Neuroma studies recruiting now, 4 set no upper age limit and 3 stop at 75 or younger; none take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Neuroma with a site in United States, or all of them as a file.
02

Study summary

PROSPECTIVE COHORT EVALUATION OF NEUROCAP® In the Treatment of symptomatic Neuroma (PROTECT Neuro)

This post-market surveillance study is conducted to provide post market surveillance information regarding long-term performance and ease of use of the Polyganics nerve capping device (NEUROCAP®) for reduction of the development of peripheral symptomatic end-neuroma.

Read the detailed description
  1. Device description NEUROCAP®, a bioresorbable nerve capping device based upon the NEUROLAC® nerve guide, is indicated to protect a peripheral nerve end and to separate the nerve from surrounding environment to reduce the development of a symptomatic neuroma. NEUROCAP® is composed of the same biocompatible, bioresorbable copolyester composing the NEUROLAC® nerve guide, Poly(68/32[15/85 D/L] Lactide-Ԑ-Caprolactone) (PLCL).
  2. Objective This post-market surveillance study is conducted to provide post market surveillance information regarding long-term performance and ease of use of the Polyganics nerve capping device (NEUROCAP®) for reduction of the development of peripheral symptomatic end-neuroma.
  3. Study design This post-market surveillance study consists of a cohort study to provide post market surveillance information regarding long-term performance and ease of use of the NEUROCAP® for reduction of the development of peripheral symptomatic end-neuroma in the upper and lower extremity. Sub analyses will be performed regarding demographics and medical background.
03

Conditions studied

  • Neuroma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Peripheral symptomatic end-neuroma patients indicated for surgical treatment of the neuroma.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects who are able to provide a written prior to participating in the clinical investigation.
  2. Subjects who are able to comply with the follow-up or other requirements.
  3. Subjects who are ≥ 18 years old.
  4. Subjects with a diagnosis of peripheral symptomatic (end-) neuroma in the upper limb.
  5. Subjects with a positive Tinel's sign.
  6. Symptomatic neuroma confirmed by pain relief following a 10min ± 2min nerve block with Xylocaine (Lidocaine) - Pain relief defined as minimally 50% reduction in VAS questionnaire score.
  7. Subjects that are indicated for surgery to treat symptomatic neuroma.

Exclusion criteria

Exclusion Criteria:

  1. Subjects who do not complete the .
  2. Subjects who are not willing to follow post-surgery protocols (e.g. avoiding pressure on the implant zone or immobilization).
  3. Subjects who are unable to comply with the follow-up or other requirements and/or have a of less than 24 months.
  4. Subjects with congenital neuropathy.
  5. Insufficient amount of soft tissue to cover the device, as assessed by the surgeon. Use of the device over a joint is advised against.
  6. Subjects who have had historical radiotherapy in the area of the (end-) neuroma.
  7. Subjects who have a known allergy to anesthetic agent or bioresorbable copolyester Poly(68/32[15/85 D/L] Lactide-ε-Caprolactone) (PLCL).
  8. Proximal nerve end > 8mm.
  9. Pregnancy.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
73 participants (actual)
Patient registry
No

Groups and cohorts

  • Treatment Group

    All subjects receiving the Neurocap® device when surgically treated for their symptomatic peripheral end-neuroma.

    Device: Neurocap®

Interventions

  • DeviceNeurocap®

    NEUROCAP®, a bioresorbable nerve capping device based upon the NEUROLAC® nerve guide, is indicated to protect a peripheral nerve end and to separate the nerve from surrounding environment to reduce the development of a symptomatic neuroma.

06

What researchers measure

Primary outcomes

  1. Visual Analog Scale (VAS) for Pain

    Subjective pain score as indicated by the patient on a scale of 1-100.

    Time frame: 2 years

Secondary outcomes

  1. Recurrence of Neuroma

    Recurrence of neuroma as assessed by clinical assessment by the surgeon.

    Time frame: 2 years

  2. Elliot Neuroma questionnaire

    Type of pain

    Time frame: 2 years

  3. QuickDASH

    Daily functioning upper limb

    Time frame: 2 years

  4. Goals questionnaire

    Daily functioning lower limb

    Time frame: 2 years

  5. Type of Pain Medication

    Type of pain medication currently taken

    Time frame: 2 years

  6. Amount of Pain Medication

    Amount of pain medication currently taken

    Time frame: 2 years

07

Study locations

16 sites
  • Arizona Center for Hand Surgery
    Phoenix, Arizona 85004, United States
  • Stanford Medical Center Hand and Upper Limb Center
    Redwood City, California 94063, United States
  • Buncke Clinic
    San Francisco, California 94114, United States
  • Veterans affairs Medical Center Portland
    Portland, Oregon 97239, United States
  • Geisinger Clinic
    Danville, Pennsylvania 17822, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104-6061, United States
  • The Philadelphia Hand Center (affiliated to Thomas Jefferson Hospital)
    Philadelphia, Pennsylvania 19107, United States
  • Virginia Commonwealth University Medical Center
    Richmond, Virginia 23219, United States
  • Clinique Chirurgicale Victor Hugo Paris
    Paris, France
  • BG Trauma Center Frankfurt am Main GmbH
    Frankfurt am Main, 60389, Germany
  • Ospedale San Guiseppe Milano
    Milano, Italy
  • Parc Sanitari Sant Joan de Deu
    Barcelona, Spain
  • Sahlgrenska University Hospital Gothenburg
    Goteborg, Sweden
  • University Hospital Linköping
    Linkoping, Sweden
  • University Hospital Lund - Department of Hand Surgery
    Malmo, Sweden
  • Birmingham Hand Centre
    Birmingham, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2017 to primary completion in Jul 2018, 14 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 8, 2016
First posted
Dec 15, 2016
StartActual
Apr 17, 2017
Primary completionActual
Jul 6, 2018
CompletionActual
Aug 30, 2020
Last update
Sep 10, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02993276
Lead sponsor
Polyganics BV
Responsible party
Sponsor
First posted
Dec 15, 2016
Start date
Apr 17, 2017
Primary completion
Jul 6, 2018
Completion
Aug 30, 2020
Last update
Sep 10, 2020

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion